Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL712716 | 0.98 | LCK (0.48) | POLBGAAALDH1A1LCKBCHE | |
| SCHEMBL10962715 | 0.95 | POLB (0.47) | POLBGAAALDH1A1LCKBCHE | |
| SCHEMBL716384 | 0.94 | ALDH1A1 (0.52) | POLBGAAALDH1A1AR | |
| SCHEMBL7877735 | 0.91 | ALDH1A1 (0.48) | POLBGAAALDH1A1BCHEHDAC3 | |
| SCHEMBL151627 | 0.90 | ALDH1A1 (0.52) | POLBGAAALDH1A1HDAC3HDAC1 | |
| SCHEMBL17508109 | 0.89 | ALDH1A1 (0.47) | POLBGAAALDH1A1BCHEHDAC3 | |
| SCHEMBL13426179 | 0.89 | LCK (0.47) | POLBGAAALDH1A1LCK | |
| SCHEMBL154270 | 0.87 | ALDH1A1 (0.48) | POLBGAAALDH1A1BCHEHDAC3 | |
| SCHEMBL8987713 | 0.85 | HDAC3 (0.49) | POLBGAAALDH1A1BCHEHDAC3 | |
| Hydrochloric Acid SCHEMBL11203276 | 0.85 | ALDH1A1 (0.47) | POLBGAAALDH1A1BCHEHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803804-B2 | Substituted pyrazines for use in the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-09-28 | — | — | US | disclosed |
| US-20080312217-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312217-A1 | Organic Compounds | TRPA1, TRPV1, CHRM1 | POLB 3189/4885GAA 3452/4885ALDH1A1 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.